Fennec announces appointment of Marco Brughera to the board
Since January 2011, Dr. Brughera has held several positions for the Sigma-Tau Group, including CEO and Global Head of Sigma Tau Rare Disease, President of Sigma-Tau Research and President of Sigma-Tau Pharmaceuticals.
He also successfully out-licensed the Defibrotide US rights to Jazz Pharmaceuticals to Baxalta. From 2004 to 2010, Dr. Brughera served as the Vice President of Preclinical Development at Nerviano Medical Sciences (NMS), a pharmaceutical oncology-focused integrated discovery and development company.
He also served as the Managing Director at Accelera, an independent contract research organization with the NMS Group.
From 1999 to 2004, Dr. Brughera held several senior level positions in the areas of research and development with Pharmacia and Pfizer.
Prior to 1999, he held various positions at Pharmacia & Upjohn and Farmitalia Carlo Erba SpA, an Italian pharmaceutical company.
He currently serves on the Board of Solgenix and Lee’s Pharmaceutical and until early 2014 was a member of the Board of Gentium SpA.
Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist. ■
LATEST MOVES FROM North Carolina
- Thomas Built Buses got VP of operations
- Executive chairman Martin R. Benante to retire from Curtiss-Wright
- Bank of America elects Brian Moynihan as chairman
- Tantalus appoints Dermot O'Leary as COO
- Marken appoints Paul J. Rice to head EMEA region
More inside POST
Nomura Q4 net revenue $3.1 billion Earnings